Neomatrix mission is to generate the fastest next generation cancer vaccines to selectively eliminate tumor cells in the body.

Our proprietary platform is unique and combines a deep knowledge of cancer biology and Immuno-Oncology, cutting-edge technologies to identify patient’s tumor neoantigens, innovative design and production of fully-synthetic, personalized DNA vaccines, a potent delivery system to maximize the immune response and the synergic effect with immune checkpoint inhibitors.

Latest News

5 June, 2023
NEOMATRIX CONCLUDES SUCCESSFUL FUNDRAISING TO SUPPORT DISCOVERY AND DEVELOMENT OF PERSONALIZED CANCER VACCINES

The biotech Neomatrix today announced that it has closed a seed funding of EUR 2 millions led by 2Invest AG and i2i Capital Limited. The funds will be used to support discovery and development of personalized cancer vaccines based on innovative DNA technology. Neomatrix approach combines a deep knowledge in cancer biology, the prediction of “neoantigens”, i.e. the flags that allow the immune system to (read more)